Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome

Acta Obstetricia et Gynecologica Scandinavica

Volumn 92, Issue 12, 2013, Pages 1369-1374

  Sahmay, Sezai ^a   Atakul, Nil ^b   Aydogan, Begüm ^b   Aydin, Yavuz ^a   Imamoglu, Metehan ^b   Seyisoglu, Hakan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

anti M llerian hormone; diagnosis of polycystic ovary syndrome; elevated anti M llerian hormone; hyperandrogenism

Indexed keywords

ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; PROLACTIN; THYROTROPIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; THYROTROPIN BLOOD LEVEL;

ANTI-MÜLLERIAN HORMONE; DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME; ELEVATED ANTI-MÜLLERIAN HORMONE; HYPERANDROGENISM;

ADULT; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPERANDROGENISM; LUTEINIZING HORMONE; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PROLACTIN; ROC CURVE; SENSITIVITY AND SPECIFICITY; THYROTROPIN;

EID: 84889255094     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12247     Document Type: Article

References (26)

1. Norman RJ, Dewailly D, Legro RS, Hickey TE,. Polycystic ovary syndrome. Lancet. 2007; 9588: 685-97. (Pubitemid 47285318)
2. Zawadzki J, Dunaif A,. Diagnostic criteria for polycystic ovary syndrome: toward a rational approach. In:, Dunaif A, Givens J, Haseltine F, Merriam G, (eds). Polycystic ovarian syndrome. Boston, MA: Blackwell, 1992. pp. 377-84.
3. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19: 41-7.
4. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009; 91: 456-88.
5. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ,. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010; 25: 544-51.
6. Wang JG, Nakhuda GS, Guarnaccia MM, Sauer MV, Lobo RA,. Müllerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am J Obstet Gynecol. 2007; 196: 77.e1-5.
7. Somunkiran A, Yavuz T, Yucel O, Ozdemir I,. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2007; 134: 196-201. (Pubitemid 47451601)
8. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004; 10: 77-83. (Pubitemid 38196508)
9. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to ovarian follicle excess and to follicular arrest. J Clin Endocrinol Metab. 2003; 88: 5957-62. (Pubitemid 38033078)
10. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, et al. Serum anti-Müllerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010; 94: 1118-21.
11. Jonard S, Robert Y, Dewailly D,. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum Reprod. 2005; 20: 2893-8. (Pubitemid 41487648)
12. Pigny P, Jonard S, Robert Y, Dewailly D,. Serum anti-Müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91: 941-5. (Pubitemid 43357762)
13. Li L, Chen X, Mo Y, Chen Y, Wenig M, Yang D,. Elevated serum anti-Müllerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr. 2010; 122: 519-24.
14. Wachs DS, Coffler MS, Malcom PJ, Chang RJ,. Serum anti-Müllerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab. 2007; 92: 1871-4. (Pubitemid 46997202)
15. Dewailly D, Pigny P, Soudan B, Catteau-Jonard S, Decanter C, Poncelet E, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010; 95: 4399-405.
16. Park AS, Lawson MA, Chuan SS, Oberfield SE, Hoeger KM, Witchel SF, et al. Serum anti-Müllerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab. 2010; 95: 1786-92.
17. Woo HY, Kim KH, Rhee EJ, Park H, Lee MK,. Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012; 59: 781-90.
18. Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME,. Serum Müllerian-inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril. 2005; 84: 938-44. (Pubitemid 41414584)
19. Cho LW, Jayagopal V, Kilpatrick ES, Holding S, Atkin SL,. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem. 2006; 43: 217-9. (Pubitemid 43668155)
20. Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN,. Which hormone tests for the diagnosis of polycystic ovary syndrome? Br J Obstet Gynaecol. 1992; 99: 232-8.
21. Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF Jr,. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988; 66: 165-72. (Pubitemid 18027747)
22. Sahmay S, Guralp O, Senturk LM, Imamoglu M, Kucuk M, Irez T,. Serum anti-mullerian hormone concentrations in reproductive age women with and without polycystic ovary syndrome: the influence of body mass index. Reprod Med Biol. 2011; 10: 113-20.
23. Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I,. Serum anti-Mullerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet. 2011; 28: 1197-203.
24. Sahmay S, Cetin M, Ocal P, Kaleli S, Senol H, Birol F, et al. Serum anti-Müllerian hormone level as a predictor of poor ovarian response in in vitro fertilization patients. Reprod Med Biol. 2011; 10: 9-14.
25. Vosnakis C, Georgopoulos NA, Rousso D, Mavromatidis G, Katsikis I, Roupas ND, et al. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2013; 29: 242-5.
26. Nascimento AD, Lara LA, Rosa-E-Silva AC, Ferriani RA, Reis RM,. Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. Gynecol Endocrinol. 2013; 29: 246-9.